Loading company…
Neurogastrx, Inc. is a biopharmaceutical company developing therapies for gastrointestinal disorders in the enteric nervous system.
Founded in 2012 and headquartered in Woburn, US, Neurogastrx, Inc. targets problems such as nausea and vomiting linked to GLP-1 agonists and gastroparesis. Its products are commercialized through healthcare providers that prescribe them, with reimbursement from payers. The company completed a USD 60.00 mn Series B round led by Vivo Capital in August 2021 and has completed three funding rounds. Its CEO is James O'Mara.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in